CancerNetwork®
@CancerNetwrk
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.
27-02-2009 21:48:14
18,8K Tweets
27,8K Followers
564 Following
Treatment with cretostimogene grenadenorepvec appears tolerable among patients with high-risk BCG–unresponsive NMIBC in the phase 3 BOND-003 trial. #blcsm #AUA24 | Amer. Urol. Assn. Mark Tyson
cancernetwork.com/view/novel-onc…